Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-527 in advanced malignancies
NCT04440943Phase 1Completed
- Sponsor
- Celldex Therapeutics
- Start
- Aug 2020
- Primary completion
- Apr 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of yivoximab in solid tumor, sponsored by Celldex Therapeutics. Primary endpoint: Safety and Tolerability of CDX-527. Started Aug 2020; status: completed.
02
Drugs
yivoximab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04440943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440943.